PROGRAM GOALS AND CONTENT OVERVIEW:

As new clinical data continues to emerge as a result of ongoing research in breast cancer diagnostics and therapeutics, official Best of SABCS® programs cover these important developments in each of four live, regional virtual events. Each regional event provides an educational forum for local researchers and clinicians to discuss the most pertinent basic, translational, and clinical breast cancer research presented at the annual SABCS® meeting.

Topics and discussions for each Best of SABCS® program are drawn from key presentations at SABCS® 2021, focusing on results of breast cancer research that helps clinicians understand current trends and forthcoming treatments that will optimize patient care outcomes. Significantly important content from SABCS® includes new drug therapy approvals and clinical trial results, updates in breast cancer screening and diagnostics, and best practices to be implemented in clinical care of patients.

The goals of the Best of SABCS® programs are to review and critically assess practice-changing results of emerging breast cancer research, propose best practices for implementing diagnostic and therapeutic strategies, and close knowledge and clinical practice gaps in the management of patients with breast cancer.

LEARNING OBJECTIVES:

1. IDENTIFY factors that predispose individuals and increase their risk of developing breast cancer.

2. DESCRIBE prognostic and predictive molecular signatures and biomarkers that can identify the most appropriate treatment strategies for individuals with breast cancer.

3. DISCUSS scientific advances from the laboratory that have great potential to translate into increased knowledge of breast cancer biology and pathogenesis.

4. REVIEW new results from clinical trials in all aspects of breast cancer care presented during oral, poster and educational sessions at the annual San Antonio Breast Cancer Symposium.

5. DISCUSS results of evidence from preclinical research and clinical trials that support the rational combinations of traditional and newer pharmacologic interventions, with a focus on novel therapeutics and resistance mechanisms.

6. DEVELOP appropriate individualized treatment strategies for those patients who would benefit from new treatments in all the major subtypes of breast cancer and also focus on reversing resistance to commonly used therapies.

ACCREDITATION STATEMENT

The UT Health San Antonio Joe R. & Teresa Lozano Long School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity has been approved for AMA PRA Category 1 Credits™

TARGET AUDIENCE

The target audience includes oncologists, medical residents, and fellows training in oncology subspecialties, nurses, nurse practitioners, physician assistants, and breast cancer researchers involved in medical, surgical, gynecologic, and radiation oncology, as well as other appropriate health care professionals.